Lannett launches 2 generics
Lannett is offering venlafaxine extended release tablets in dosage strengths of 150 mg and 225 mg, and lidocaine topical solution 4%.
Venlafaxine is the generic of Pfizer’s Effexor.
Venlafaxine ER tablets, 150 mg and 225 mg, and lidocaine topical solution 4% had a market value of approximately $150 million and $17 million, respectively, for the 12 months ended November 2019, although actual generic market values are expected to be lower.
"Both venlafaxine ER tablets and lidocaine topical solution 4% are solid additions to our offering and add to our recent wave of product launches," said Tim Crew, Lannett CEO, adding, "Venlafaxine ER is a partnered product and the lidocaine topical solution 4% is a product we acquired in May 2018 from a subsidiary of Endo International."